Current and Emerging Data on SGLT2 Inhibitors in Heart Failure

Overview

The opportunity for cardiovascular disease prevention in patients with type 2 diabetes mellitus (T2DM) has recently expanded with antihyperglycemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE) including sodium-glucose co-transporter-2 (SGLT2) demonstrating robust reductions in heart failure (HF). Although the exact mechanisms of cardiovascular (CV) benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects.

Recent trials — including the recently presented DAPA-HF — have provided further insight into the effectiveness of SGLT2 inhibitors in patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) in the absence of T2DM.

 

Target Audience

This programme is intended to educate:

  • Heart Failure Specialists

  • General Cardiologists

Learning Objectives

  • Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data;

  • differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF);

  • apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF;

  • assess the interrelationships linking diabetes, HF and CVD;

  • interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.

Disclosures

In compliance with EBAC / EACCME guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. 

The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

This activity has been supported by an unrestricted educational grant from AstraZeneca.

R-CME Disclaimer / Terms & Conditions

Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

 

Course summary
Available credit: 
  • 1.00 European Board for Accreditation in Cardiology (EBAC)
Course opens: 
10/23/2019
Course expires: 
07/31/2024
Cost:
£0.00
Rating: 
5

Course Director

Professor Felipe Martinez, Universidad Nacional de Córdoba, Córdoba, AR

Presenters

Prof Scott Solomon, Harvard Medical School, Boston, MA, US

Prof Andrew Coats, Monash University Melbourne, Melbourne, AU

Prof Carolyn Lam, University of Singapore, Singapore, SG

Prof Lars Lund, Karolinska Institutet, Stockholm, SE

Prof Frank Ruschitzka, University hospital Zurich, Zurich, CH

Prof John McMurray, University of Glasgow, Glasgow, UK

 

Please note that relevant faculty disclosures are included in the presentations.
This activity has been supported by an unrestricted educational grant from AstraZeneca.
 

The event ‘Current and Emerging Data on SGLT2 Inhibitors in Heart Failure’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.

 

Available Credit

  • 1.00 European Board for Accreditation in Cardiology (EBAC)

Price

Cost:
£0.00
Please login or register to take this course.